A new subgroup analysis across the MONALEESA phase III program found that patients with visceral metastases who were treated with Kisqali (ribociclib) plus endocrine therapy in the first-line setting achieved a median OS of 62.7 months compared to 52.1 months for those treated with endocrine therapy alone.
In 1991, the National Breast Cancer Coalition demanded that the federal government spend $300 million more on breast cancer research. This push resulted in the creation of the Department of Defense Congressionally Directed Medical Research Program, which has broadened to 34 other diseases with an FY24 budget of $1.5 billion.
